Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadnersen - Ionis Pharmaceuticals

Next Previous
Drug Profile

Tadnersen - Ionis Pharmaceuticals

Alternative Names: BIIB-078; BIIB-078 free acid; IONIS-C9Rx; Tadnersen sodium - Ionis Pharmaceuticals

Latest Information Update: 31 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action C9orf72 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Mar 2022 Discontinued - Phase-I for Amyotrophic lateral sclerosis (Adjuvant therapy) in Ireland, United Kingdom, Switzerland, Switzerland, Netherlands, Canada, USA (Intrathecal) due to unmet secondary efficacy endpoints and no clinical benefits (NCT04288856)
  • 28 Mar 2022 Efficacy and adverse events data from a phase I trial in Amyotrophic lateral sclerosis released by Biogen and Ionis Pharmaceuticals
  • 28 Mar 2022 Biogen discontinues a phase I trial in Amyotrophic lateral sclerosis (Adjuvant therapy) in USA (Intrathecal) due to unmet secondary efficacy endpoints and no clinical benefits (NCT04288856)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top